Neuropathix (NPTX) 10-Q 13 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 13, 2019
Document And Entity Information
Entity Registrant Name	Kannalife Inc
Entity Central Index Key	0001615999
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current?	Yes
Is Entity Emerging Growth?	true
Is Entity Small Business?	true
Entity Extended Transition Period?	false
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		69,854,141
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 537,087	$ 307,131
Marketable security (available for sale)	805,500	2,579,640
Other receivables	50,211	99,691
Due from related party, net	2,456	16,334
Total Current Assets	1,395,254	3,002,796
Other assets	27,490
Property and equipment, net	2,769	3,074
Security deposits	17,121	17,121
TOTAL ASSETS	1,442,634	3,022,991
CURRENT LIABILITIES:
Accounts payable and accrued expenses	327,949	283,996
Payroll and related liabilities	249,537	246,067
Loan payable - related party	42,092	16,173
Total Current Liabilities	619,578	546,236
LONG TERM LIABILITIES:
Loan payable - long term	620,000	620,000
Loan payable - related party - long term		25,822
Convertible notes payable - long term	500,000	500,000
Total Long Term Liabilities	1,120,000	1,145,822
TOTAL LIABILITIES	1,739,578	1,692,058
STOCKHOLDERS' EQUITY:
Common stock, $0.0001 par value, 200,000,000 authorized, 69,854,141 issued and outstanding	6,985	6,985
Additional paid-in capital	6,386,793	6,381,755
Accumulated deficit	(6,680,091)	(5,052,051)
Non-controlling interest	(10,631)	(5,756)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	(296,944)	1,330,933
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	1,442,634	$ 3,022,991
Series A Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized; Series A preferred stock, 75 shares designated, 75 issued and outstanding (Liquidation preference of $75,000); Series B preferred stock, 75 shares designated, 75 issued and outstanding (Liquidation preference of $75,000)
Series B Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized; Series A preferred stock, 75 shares designated, 75 issued and outstanding (Liquidation preference of $75,000); Series B preferred stock, 75 shares designated, 75 issued and outstanding (Liquidation preference of $75,000)

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Preferred Stock, Par or Stated Value Per Share	$ .0001
Preferred Stock, Shares Authorized	5,000,000
Common Stock, Par or Stated Value Per Share	$ .0001
Common Stock, Shares Authorized	200,000,000
Common Stock, Shares, Issued	69,854,141
Common Stock, Shares, Outstanding	69,854,141
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized	75	75
Preferred Stock, Shares Issued	75	75
Preferred Stock, Shares Outstanding	75	75
Liquidation preference	$ 75,000	$ 75,000
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized	75	75
Preferred Stock, Shares Issued	75	75
Preferred Stock, Shares Outstanding	75	75
Liquidation preference	$ 75,000	$ 75,000

Condensed Consolidated Statment

Condensed Consolidated Statments of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
NET REVENUES:
Grant Revenue	$ 52,768	$ 36,858	$ 102,059	$ 66,864
TOTAL NET REVENUES	52,768	36,858	102,059	66,864
OPERATING EXPENSES:
Research and development	148,959	34,871	250,237	58,637
General and administrative	458,581	95,311	909,767	187,435
TOTAL OPERATING EXPENSES	607,540	130,182	1,160,004	246,072
LOSS FROM OPERATIONS	(554,772)	(93,324)	(1,057,945)	(179,208)
OTHER EXPENSE:
Interest expense, net	(15,980)	(4,514)	(31,960)	(8,150)
Other (expense) income, net		31,183		31,183
Loss on conversion of convertible debt				(61,815)
Realized gain on investment		3,901,974		3,901,974
Net gains and losses recognized during the period on equity securities	(213,664)		(543,010)
TOTAL OTHER EXPENSE	(229,644)	3,928,643	(574,970)	3,863,192
NET (LOSS) INCOME BEFORE INCOME TAX	(784,416)	3,835,319	(1,632,915)	3,683,984
Income tax expense (benefit)		772,000		772,000
NET (LOSS) INCOME	(784,416)	3,063,319	(1,632,915)	2,911,984
Net loss attributable to noncontrolling interests	(2,341)		(4,875)
Net (loss) income attributable to Kannalife, Inc.	$ (782,075)	$ 3,063,319	$ (1,628,040)	$ 2,911,984
(Loss) income attributable to Kannalife, Inc. per common share - basic	$ (0.01)	$ 0.05	$ (0.02)	$ 0.05
(Loss) income attributable to Kannalife, Inc. per common share - diluted	$ (.01)	$ .05	$ (.02)	$ .05
Weighted average common shares outstanding - basic	69,854,141	60,324,141	69,854,141	60,207,419
Weighted average common shares outstanding - diluted	69,854,141	60,324,141	69,854,141	60,207,419

Condensed Consolidated Statemen

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (1,632,915)	$ 2,911,984
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Loss on issuance of stock for conversion of notes payable and accrued interest		61,815
Realized gain on investment		(3,901,974)
Net gains and losses recognized during the period on equity securities	213,664
Depreciation	305
Issuance of options for services	5,038	5,038
Provision for deferred income taxes		772,000
Changes in operating assets and liabilities:
Security deposits		(2,121)
Other receivables	49,480
Accounts payable and accrued expenses	43,953	(151,257)
Payroll and related liabilities	3,470	3,885
Due from related party, net	13,878
NET CASH USED IN OPERATING ACTIVITIES	(1,303,127)	(300,630)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of marketable securities	1,560,476
Purchase of other asset	(27,490)
NET CASH PROVIDED BY INVESTING ACTIVITIES	1,532,986
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable		345,000
Proceeds from notes payable - related party	97
NET CASH PROVIDED BY FINANCING ACTIVITIES	97	345,000
Net increase in cash	229,956	44,370
Cash and cash equivalents, beginning of period	307,131	4,326
Cash and cash equivalents, end of period	537,087	48,696
Non-cash activities:
Issuance of common stock for conversion of notes payable and accrued interest		592,280
Issuance of common stock for conversion of accrued salaries		$ 2,812,811

Condensed Consolidated Statme_2

Condensed Consolidated Statments of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Noncontrolling Interest	Total
Beginning balance, Shares at Dec. 31, 2017			53,281,962
Beginning balance, Amount at Dec. 31, 2017			$ 5,328	$ 2,683,776	$ (5,988,866)		$ (3,299,762)
Issuance of stock for conversion of notes payable			1,537,009
Issuance of stock, value for conversion of notes payable			$ 153	653,940			654,093
Issuance of stock for conversion of accrued salaries			5,505,200
Issuance of stock, value for conversion of accrued salaries			$ 551	2,812,260			2,812,811
Issuance of stock options for services				2,519			2,519
Net income (loss)					(151,335)		(151,335)
Ending balance, Shares at Mar. 31, 2018			60,324,141
Ending balance, Amount at Mar. 31, 2018			$ 6,032	6,152,495	(6,140,201)		18,326
Issuance of stock options for services				2,520			2,520
Net income (loss)					3,063,319		3,063,319
Ending balance, Shares at Jun. 30, 2018			60,324,141
Ending balance, Amount at Jun. 30, 2018			$ 6,032	6,155,015	(3,076,882)		3,084,165
Beginning balance, Shares at Dec. 31, 2018	75	75	69,854,141
Beginning balance, Amount at Dec. 31, 2018			$ 6,985	6,381,755	(5,052,051)	(5,756)	1,330,933
Issuance of stock options for services				2,519			2,519
Net income (loss)					(845,965)	(2,534)	(848,499)
Ending balance, Shares at Mar. 31, 2019	75	75	69,854,141
Ending balance, Amount at Mar. 31, 2019			$ 6,985	6,384,274	(5,898,016)	(8,290)	484,953
Beginning balance, Shares at Dec. 31, 2018	75	75	69,854,141
Beginning balance, Amount at Dec. 31, 2018			$ 6,985	6,381,755	(5,052,051)	(5,756)	1,330,933
Issuance of stock options for services							2,519
Ending balance, Shares at Jun. 30, 2019	75	75	69,854,141
Ending balance, Amount at Jun. 30, 2019			$ 6,985	6,386,793	(6,680,091)	(10,631)	(296,944)
Beginning balance, Shares at Mar. 31, 2019	75	75	69,854,141
Beginning balance, Amount at Mar. 31, 2019			$ 6,985	6,384,274	(5,898,016)	(8,290)	484,953
Issuance of stock options for services				2,519			2,519
Net income (loss)					(782,075)	(2,341)	(784,416)
Ending balance, Shares at Jun. 30, 2019	75	75	69,854,141
Ending balance, Amount at Jun. 30, 2019			$ 6,985	$ 6,386,793	$ (6,680,091)	$ (10,631)	$ (296,944)

Organization and Nature of Oper

Organization and Nature of Operations	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	Note 1 – Organization and Nature of Operations Kannalife, Inc. (the “Company”) was incorporated under the laws of the state of Delaware on March 25, 2013 under the name TYG Solutions Corp. The Company consummated a share exchange transaction on July 25, 2018 with Kannalife Sciences, Inc. (“Kannalife”), a privately held Delaware corporation formed in 2010, the accounting acquirer. Upon completion of the share exchange transaction, Kannalife is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of Kannalife the surviving entity and accounting acquirer. All references that refer to (the “Company” or “we” or “us” or “our”) are Kannalife, unless otherwise differentiated. Kannalife is a phytomedical/pharmaceutical company that specializes in the research and development of synthetic molecules and therapeutic products derived from botanical sources, including the cannabis taxa. Share Exchange and Corporate Restructuring On July 25, 2018, the Company entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Kannalife Sciences, Inc., a Delaware corporation (“Kannalife”) and certain stockholders of Kannalife (the “Kannalife Stockholders”). Pursuant to the terms of the Share Exchange Agreement, the Company acquired approximately 99.7% of the issued and outstanding shares of Kannalife by means of a share exchange with the Kannalife Stockholders in exchange for 60,324,141 newly issued shares of the common stock of the Company (the “Share Exchange”), which increased the Company's issued and outstanding shares of common stock to 69,854,141. As a result of the Share Exchange, Kannalife became a 99.7% owned subsidiary of the Company, which on a going forward basis will result in consolidated financial reporting by the Company to include the results of Kannalife. The initial closing of the Share Exchange occurred concurrently with entry into the Share Exchange Agreement (the “Initial Closing”). After the Initial Closing and for a period of no more than 120 days thereafter, unless extended in the sole discretion of the Company, the Company may issue, on the same terms and conditions as those contained in the Share Exchange Agreement, additional shares of the common stock of the Company to Kannalife Stockholders that did not participate in the Initial Closing, provided that each additional Kannalife Stockholder becomes a party to the transaction documents (the “Additional Closing”). The Share Exchange has been accounted for as a reverse acquisition of the Company by Kannalife but in substance as a capital transaction, rather than a business combination since the Company had nominal operations and assets prior to and as of the closing of the Share Exchange. The former stockholders of Kannalife represent a significant constituency of the Company’s voting power immediately following the Share Exchange and Kannalife’s management has assumed operational, financial and governance control. The transaction is deemed a reverse recapitalization and the accounting is similar to that resulting from a reverse acquisition, except that no goodwill or other intangible assets should be recorded. For accounting purposes, Kannalife is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of Kannalife. All references to common stock, share and per share amounts have been retroactively restated to reflect the reverse recapitalization as if the transaction had taken place as of the beginning of the earliest period presented. Company assets and liabilities pre-acquisition: Cash and cash equivalents $ 289,654 Note receivable 142,500 Total assets $ 432,154 Accounts payable and accrued expenses $ 20,504 Loan payable - related party - long term 41,995 Convertible notes payable - related party 500,000 Total liabilities 562,499 Total liabilities assumed $ (130,345 ) 7 KANNALIFE, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019 (UNAUDITED) The following summarized unaudited consolidated pro forma information shows the results of operations of the Company had the reverse acquisition occurred on January 1, 2018: Pro Forma (Unaudited) Six Months Ended June 30, 2018 Total revenues $ 66,864 Net income $ 2,836,768 Net income per common share, basic $ 0.05 Net income per common share, diluted $ 0.05 The summarized unaudited consolidated pro forma results are not necessarily indicative of results which would have occurred if the acquisition had been in effect for the period presented. Further, the summarized unaudited consolidated pro forma results are not intended to be a projection of future results. Name Change On November 9, 2018, the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State that changed its name to Kannalife, Inc. The Company concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change. The Company’s name change and ticker change was reviewed and processed by FINRA and went effective January 17, 2019. Unaudited Interim Financial Information We have prepared the accompanying consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These consolidated financial statements are unaudited and, in our opinion, include all adjustments, consisting of normal recurring adjustments and accruals necessary for a fair presentation of our balance sheets, operating results, and cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for 2019. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been omitted in accordance with the rules and regulations of the SEC. These consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies The significant accounting policies used in the preparation of the consolidated financial statements are as follows: Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Kannalife. The non-controlling interest in Kannalife represents the 0.30% equity interest held by the original shareholders of Kannalife before the share exchange. All significant consolidated transactions and balances have been eliminated in consolidation. The operations of Kannalife, Inc. are included in the consolidated financial statement from the date of the Share Exchange. Significant risks and uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. 8 KANNALIFE, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019 (UNAUDITED) The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. Use of Estimates The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Company’s stock, stock based compensation, and valuation allowance relating to the Company’s deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made. Concentration Risks During the six months ended June 30, 2019, the Company’s revenue had a concentration of 100% from one grant. The concentration of the Company’s revenue creates a potential risk to future working capital in the event that the Company is not able to continue receiving the grant revenue. Joint Venture On June 18, 2019, the Company, along with MJNA which is a significant shareholder and AXIM biotechnologies whose president is affiliated with a shareholder, entered into a joint venture agreement with an industrial hemp production farm for the supply of certain industrial hemp CBD crops. The purpose of the joint venture is to share in the harvested yield of the hemp production which the Company hopes to result in a steady industrial hemp CBD supply for research and development purposes. The Company accounts for its participation in the joint venture under the equity method of accounting. Revenue Recognition The FASB issued Accounting Standards Update (“ASU”) No. 2014-09, codified as ASC 606: Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The Company adopted ASC 606 effective January 1, 2018 using modified retrospective basis and the cumulative effect was immaterial to the consolidated financial statements. Revenue consists of research funding from the Company’s National Institute of Health (“NIH”) Grant. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met. Stock Based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provision of FASB ASC 718, Compensation – Stock Compensation The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505, Equity–based Payments to Non-Employees . 9 KANNALIFE, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019 (UNAUDITED) Net Income (Loss) per Share Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 5,150,000 for the three and six months ended June 30, 2019. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was zero (0) for the three and six months ended June 30, 2018. Research and Development In accordance with FASB ASC 730, Research and Development Recently Issued Authoritative Guidance In February 2016, the FASB issued ASU, Leases, which requires lessees to recognize most leases on their balance sheets as a right-of-use asset with a corresponding lease liability. Lessor accounting under the standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required. The Company adopted the standard effective January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the following accounting policies related to this standard update: • The option to not reassess prior conclusions related to the identification, classification and accounting for initial direct costs for leases that commenced prior to January 1, 2019. • Short-term lease accounting policy election allowing lessees to not recognize right-of-use assets and liabilities for leases with a term of 12 months or less; and • The option to not separate lease and non-lease components for certain equipment lease asset categories such as freight car, vehicles and work equipment. • The package of practical expedients applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. The Company has inventoried all leases where the Company is a lessee as of the initial date of application and has examined other contracts with suppliers, vendors, customers and other outside parties to identify whether such contracts contain an embedded lease as defined under the new guidance. The Company’s lease population comprises of an office and lab, which is immaterial to the consolidated financial statements. As a result of the above, the adoption of ASC 842 did not have a material effect on the financial statements. The Company will review for the existence of embedded leases in future agreements. In June 2018, the FASB issued ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. This standard is effective for public companies for annual periods beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted as long as ASU 2014-09 has been adopted. The Company adopted the guidance on January 1, 2019. The adoption did not have a material impact on our consolidated financial statements.

Going Concern and Management's

Going Concern and Management's Liquidity Plans	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management's Liquidity Plans	Note 3 – Going Concern and Management’s Liquidity Plans The Company’s condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in our accompanying condensed consolidated financial statements, the Company has had a net loss from operations of $1,057,945 and $179,208 for the six months ended June 30, 2019 and 2018, respectively. The net cash used in operations were $1,303,127 and $300,630 for the six months ended June 30, 2019 and 2018, respectively. Additionally, the Company had an accumulated deficit of $6,680,091 at June 30, 2019 and has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. As of June 30, 2019, we had $537,087 in cash and cash equivalents. Additionally, we had $805,500 in marketable securities (available for sale). Management plans to raise additional capital through the sale of our marketable securities. We expect that between our existing cash, cash equivalents and marketable securities we will be able to sufficiently fund our operations and capital requirements for the next 12 months. The Company’s history of recurring losses, and uncertainties as to whether its operations will become profitable and generate operating cash flows raise substantial doubt about its ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4 – Fair Value Measurements The Company follows FASB ASC 820, Fair Value Measurements and Disclosures Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Pricing inputs that are generally unobservable inputs and not corroborated by market data. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The carrying amounts reported in the Company’s consolidated financial statements for cash, accounts payable and accrued expenses approximate their fair value because of the immediate or short-term nature of these financial instruments. Transactions involving related parties cannot be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm's-length transactions unless such representations can be substantiated. On March 7, 2014, Kannalife Sciences, Inc. (“Kannalife”) entered into an agreement with General Hemp LLC (“General Hemp”) through its wholly owned subsidiary Kannaway LLC (“Kannaway”) for certain rights and agreements to where each company would exchange 4.99% of each Company’s equity, by way of a stock swap. As such, Kannalife would receive a 4.99% equity stake in Kannaway and Kannaway would receive 6,408,980 shares of restricted common stock of Kannalife. On or about April 2014, Kannalife delivered 6,408,980 of the aforementioned Kannalife restricted common stock to General Hemp on behalf of Kannaway and such shares were made to Kannaway as the beneficiary. The Company recorded the fair market value of the common stock at $256,359 or $0.04 per share. The Company valued the shares based upon other transactions of the Company's common stock around the same time frame. The Company accounted for the transaction as a cost investment. 11 KANNALIFE, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019 (UNAUDITED) On or about December 2015, Medical Marijuana, Inc. (“MJNA”) purchased Kannaway from General Hemp for which due to a dispute between the Company and General Hemp, the Company wasn't provided any of the consideration. On June 1, 2018, the Company received 41,583,333 shares of MJNA common stock pursuant to a settlement agreement effective July 15, 2017. MJNA is a significant shareholder of the Company and their Chief Executive Officer is also on the Company's Board of Directors. The following table presents assets that are measured and recognized at fair value as of June 30, 2019, on a recurring basis: June 30, 2019 Level 1 Level 2 Level 3 Total Carrying Value Marketable securities – Medical Marijuana, Inc. $ 805,500 — — $ 805,500

Accrued Payroll and Payroll Tax

Accrued Payroll and Payroll Taxes	6 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Accrued Payroll and Payroll Taxes	Note 5 – Accrued Payroll and Payroll Taxes Accrued payroll and payroll taxes at June 30, 2019 and December 31, 2018 consisted of the following: 2019 2018 Payroll $ — $ — Payroll taxes 249,537 246,067 Totals $ 249,537 $ 246,067 As of June 30, 2019 and December 31, 2018, the Company had accrued payroll taxes in connection with salaries paid and accrued to four officers of the Company. In July of 2018, the Company entered into a new employment agreement with its CEO. The initial term of the agreement was for two years and automatically renews for successive one year terms. In July of 2018, the Company entered into new employment agreements with three officers. The initial term of these agreements were for one year and automatically renew for successive six month terms. See Note 13 for discussion of accrued payroll converted into common stock.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Notes Payable	Note 6 – Notes Payable During the year ended December 31, 2017, the Company borrowed $367,500 and issued a promissory note with a maturity date of October 18, 2017. This note was later amended to extend the maturity to April 18, 2019. During the year ended December 31, 2018, the Company borrowed an additional $352,500 and issued a promissory note with a maturity date of April 18, 2019. These loans incurred 3% interest per annum. On June 29, 2018, these notes were amended to extend the maturity date to July 1, 2020 and the interest rate was changed to 8% per annum. All accrued interest prior the amendment date was forgiven. Accrued interest related to these notes is $48,921 and $24,460 as of June 30, 2019 and December 31, 2018, respectively. Upon the consolidation of the Company and Kannalife, $100,000 of the above-mentioned borrowings was eliminated due to it being an intercompany transaction. The total, above mentioned, notes payable due was $620,000 as of June 30, 2019 and December 31, 2018. Total interest expense on notes payable, amounted to $12,230 and $4,514 for the three months ended June 30, 2019 and 2018, respectively. Total interest expense on notes payable, amounted to $24,460 and $8,150 for the six months ended June 30, 2019 and 2018, respectively.

Notes Payable - Related Party

Notes Payable - Related Party	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Notes Payable - Related Party	NOTE 7 – NOTES PAYABLE – RELATED PARTY Prior to the share exchange agreement, the Company borrowed $25,822 and issued a promissory note with a maturity date of March 31, 2020. The loans represent working capital advances from shareholders, are unsecured, interest bearing 0.5%, and grant a security interest in the Company’s assets as collateral. In March 2019, this note was amended and is now non-interest bearing. Accrued interest related to this note is $226 as of June 30, 2019 and December 31, 2018, respectively.

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Jun. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Convertible Notes Payable	NOTE 8 – CONVERTIBLE NOTES PAYABLE On May 15, 2015, the Company borrowed $35,000 and issued a convertible promissory note with a maturity date of April 30, 2016. The loan incurs 10% interest per annum. This note is convertible to the Company’s common stock at a price of $1.00 per share. In addition, the Company issued 17,500 warrants to purchase common stock with an exercise price of $1.50 per share and a term of two years. These warrants were valued at $7,525 on a relative fair value basis and were recorded as a debt discount to be amortized over the term. See below for discussion of settlement of liability through share exchange. On August 13, 2015, the Company borrowed $50,000 and issued a convertible promissory note with a maturity date of August 12, 2016. The loan incurs 10% interest per annum and increasing to 17% per annum in the event of a default. This note is convertible to the Company’s common stock at a price of $1.00 per share. In addition, the Company issued 25,000 warrants to purchase common stock with an exercise price of $1.50 per share and a term of two years. These warrants were valued at $10,751 on a relative fair value basis and were recorded as a debt discount to be amortized over the term. See below for discussion of settlement of liability through share exchange. On November 25, 2015, the Company borrowed $100,000 and issued a convertible promissory note with a maturity date of November 24, 2016. The loan incurs 10% interest per annum and increasing to 14% per annum in the event of a default. This note is convertible to the Company’s common stock at a price of $1.00 per share. In addition, the Company issued 50,000 warrants to purchase common stock with an exercise price of $1.50 per share and a term of two years. These warrants were valued at $21,500 on a relative fair value basis and were recorded as a debt discount to be amortized over the term. See below for discussion of settlement of liability through share exchange. Prior to the Share Exchange, the Company issued a convertible note to an investor, face value $500,000, in exchange for $500,000 in cash. The note is unsecured, bears interest at the rate of 3% per annum and matures on February 16, 2030. The note is convertible into common stock of the Company at $0.10 per share at any time at the option of the holder, subject to a 4.9% blocking provision which prohibits the holder from converting into common stock of the Company if such conversion results in the holder owning greater than 4.9% of the outstanding common stock of the Company after giving effect to the conversion. See below for discussion of settlement of liability through share exchange. On January 3, 2018, prior to the Share Exchange, the Company issued 563,063 shares of common stock (on a post-Share Exchange basis) for the conversion of $236,104 convertible notes payable and related accrued interest. The Company determined that the transaction should be recorded at fair value due to the difference between the conversion price and the price per the agreements.

Convertible Notes Payable - Rel

Convertible Notes Payable - Related Party	6 Months Ended
	Jun. 30, 2019
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract]
Convertible Notes Payable - Related Party	NOTE 9 – CONVERTIBLE NOTES PAYABLE - RELATED PARTY On December 27, 2014, the Company borrowed $150,000 from a stockholder and issued a convertible promissory note with a maturity date of December 31, 2015. The loan incurs 10% interest per annum and increasing to 17% per annum in the event of a default. This note is convertible to the Company’s common stock at a price of $1.00 per share. See below for discussion of settlement of liability through share exchange. During the year ended December 31, 2015, the Company borrowed $120,000 from the Chief Executive Officer and issued convertible promissory notes that are due on demand. The loans incur 10% interest per annum. These notes are convertible to the Company’s common stock at a price of $1.00 per share. On November 20, 2015, the Company borrowed $5,000 from the Chief Executive Officer and issued a convertible promissory note that is due on demand. The loan incurs 10% interest per annum. This note is convertible to the Company’s common stock at a price of $0.40 per share. During the year ended December 31, 2016, the Company borrowed $15,000 from the Chief Executive Officer and issued convertible promissory notes that are due on demand. The loans incur 10% interest per annum. These notes are convertible to the Company’s common stock at a price of $0.40 per share. During the year ended December 31, 2016, the Company borrowed $10,000 from the Chief Executive Officer and issued convertible promissory notes with a maturity date of December 31, 2016. The loans incur 10% interest per annum and increasing to 17% per annum in the event of a default. These notes are convertible to the Company’s common stock at a price of $0.40 per share. 13 KANNALIFE, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019 (UNAUDITED) During the year ended December 31, 2017, the Company borrowed $20,000 from the Chief Executive Officer and issued convertible promissory notes with a maturity date of December 31, 2017. The loans incur 10% interest per annum and increasing to 17% per annum in the event of a default. These notes are convertible to the Company’s common stock at a price of $0.40 per share. During the year ended December 31, 2017, the Company repaid $23,828 of principal and $16,522 of accrued interest towards the outstanding notes payable. On January 3, 2018, prior to the Share Exchange, the Company converted these notes into 973,946 shares of common stock (on a post-Share Exchange basis) for the conversion of $356,176 convertible notes payable and related accrued interest. The difference of the $58,300 balance of the notes and the fair value of the shares issued was recorded as a loss on conversion of debt. The Company determined that the transaction should be recorded at fair value due to the difference between the conversion price and the price per the agreements.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10 – Commitments and Contingencies Legal Proceedings From time to time the Company may get involved in legal proceedings arising in the ordinary course of business. Other than as set forth in “Legal Proceedings” in Part II below, the Company believes there is no litigation pending that could have, individually or in the aggregate, a material adverse effect on its results of operations or financial condition. Occupancy Leases On April 1, 2014, the Company entered into a month to month lease arrangement for office space. The monthly rent payment is $5,400 and the security deposit is $15,000. On September 15, 2015, the Company entered into a one year lease arrangement for office space. The Company has amended this lease to extend the term through June 30, 2019. The monthly rent payment is $249 and the security deposit is $183. On February 1, 2018, the Company entered into a month to month lease arrangement for laboratory space. The monthly rent payment is $500. On July 1, 2018, the Company entered into a one year lease arrangement for office space, with the option to renew the lease annually. On September 1, 2018, the Company subleased this office space to a third party. The Sublessee will pay 100% of rent for months September through November 2018 and will pay 50% of rent until expiration of lease on June 30, 2019. The monthly rent payment is $2,600 and a security deposit of $2,121. As of the filing date, the company has a month to month rental arrangement and is in talks to renew the lease. Royalty Agreements On June 12, 2012, the Company entered into a Patent License Agreement with agencies of the United States Public Health Services within the Department of Health and Human Services (“PHS”). Under the License Agreement, PHS granted the Company an exclusive right to use and develop certain patents relating to Cannabinoids as Antioxidants and Neuroprotectants. In exchange for the License, the Company has agreed to the following payments: • a $30,000 license issue royalty within 90 days of the execution of the agreement • a minimum annual royalty in the amount of $10,000 • 3% royalty on net sales from any sales of licensed products or practice of licensed processes • milestone payment of $40,000 upon initiation of first Phase I clinical trial • milestone payment of $100,000 upon initiation of first Phase II clinical trial • milestone payment of $250,000 upon completion of first Phase III clinical trial • milestone payment of $500,000 upon first marketing approval by FDA • a sublicensing royalty of 12% on the fair market value of any consideration received for granting each sublicense 14 KANNALIFE, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2019 (UNAUDITED) On December 31, 2014, the Company executed five exclusive pharmaceutical license agreements with the Company’s CEO, the Company’s CMO, three advisory board members of the Company, and an unrelated third party. These agreements provide the Company the worldwide exclusive rights to certain drug technologies and methods (and systems) for collection, processing and use of data for the dispensing of phyto-medical and botanically derived materials for consumption. The license agreements grant to the Company from the inventors the rights to develop, market, make, use, and sell certain drug formulations, which are applied to humans through the use of certain drug technology. In return for these exclusive rights from the inventors, the Company has agreed to compensate the inventors under the agreements with royalties ranging from 1.5% to 2.5% on all net sales by the Company of licensed products covered by a valid claim of a patent or patent application of the inventor patent rights. Additionally, the Company retains the rights to sublicense the drug formulations, and upon such sublicense shall pay the inventors from 1.5% up to 5% of all royalties and sublicense fees paid to the Company on account of sublicenses under the inventor patent rights and inventor technology rights, less all appropriate expenses associated with such sublicenses incurred by the Company. However, if the inventor supplies licensed products to sublicensees of the Company pursuant to such sublicenses, the inventor shall supply such licensed products at its cost. Prior to the Share Exchange this royalty agreement was terminated.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 11 – Related Party Transactions The Company’s Chief Executive Officer shares the use of the leased office space for personal living quarters. From time to time the Company sends money to Golden Gate Capital (“GGCP”), a company owned by our CEO, for the advances of certain expenses and to be deposited into the bank account of Kannalife. Due to the timing of the funds transferred and expenses incurred, at times, there remains a balance due from GGCP. As of June 30, 2019, $2,456 is due from GGCP. Subsequent to the period end, GGCP has transferred all the remaining funds to Kannalife. As of the filing of these financial statements, there is no outstanding balance due from GGCP. See Notes 7, 9 and 13 for additional related party transactions.

Marketable Security

Marketable Security	6 Months Ended
	Jun. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Marketable Security	Note 12 – Marketable Security On June 1, 2018, the Company received 41,583,333 shares of Medical Marijuana, Inc. (“MJNA”) common stock pursuant to a settlement agreement. In 2014, the Company entered into a revenue sharing agreement with Kannaway LLC, whereas, among the considerations and obligations the parties agreed to a share exchange, whereby the Company issued 6,408,980 shares of its common stock in exchange of 4.99% ownership of Kannaway. A significant shareholder of the Company owned the remaining ownership of Kannaway LLC. Subsequently, Kannaway was sold, by its parent company, to MJNA for 833,333,333 shares of MJNA common stock. The settlement agreement called for the release of all obligations in exchange for the issuance of 41,583,333 shares of common stock in MJNA to the Company. The investment in MJNA has been recorded as an investment in non-consolidated entities and is revalued every quarter with fluctuations in fair value recorded to earnings. The fair value of the investment is based on the closing price of the shares reported on the principal stock exchange on which they are traded. At June 30, 2019 the Company held 15,000,000 shares of MJNA which traded at a closing price of $0.0537, or value of $805,500. In the following table, gains/losses on equity securities sold in the period reflect the difference between proceeds from sales and the fair value of the equity security sold at the beginning of the period or the purchase date, if later. See note 4 for additional information. The following table summarizes the gains and losses recognized during the three month period ending June 30, 2019: Net gains and (losses) recognized during the period on equity securities $ (213,664 ) Less: Net gains and (losses) recognized during the period on equity securities sold during the period 104,165 Unrealized gains and (losses) recognized during the period on equity securities still held at the reporting date $ (109,499 ) The following table summarizes the gains and losses recognized during the six month period ending June 30, 2019: Net gains and (losses) recognized during the period on equity securities $ (543,010 ) Less: Net gains and (losses) recognized during the period on equity securities sold during the period 91,011 Unrealized gains and (losses) recognized during the period on equity securities still held at the reporting date $ (451,999 )

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Stockholders' Equity	Note 13 – Stockholders’ Equity Series A Preferred Stock – Kannalife Pre-Share Exchange In July 2018, prior to the Share Exchange, the Company converted 4,893,510 shares of preferred stock into 4,893,510 shares of common stock (on a post-Share Exchange basis). Series A Preferred Stock Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series A Preferred Stock. Each share of the Series A Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Company’s board of directors and any annual or special meeting and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share. In July 2018, the Company issued 75 shares of Series A Preferred Stock, to Naturewell, Inc., an entity controlled by the former CEO of TYG Solutions, Inc., in exchange for $75,000. Series B Preferred Stock Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series B Preferred Stock. Each share of the Series B Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series B Preferred Stock are entitled to elect up to three (3) directors to the Company’s board of directors and any annual or special meeting and have preferential rights in regard to the election of Series B directors. In all other voting matters, the holders of Series B Preferred Stock are entitled to cast 1,000 votes per share. In July 2018, the Company issued 75 shares of Series B Preferred Stock, to our CEO, in exchange for $75,000. Common Stock The Company is authorized to issue 200,000,000 shares of $0.0001 par value common stock. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders. On January 3, 2018, prior to the Share Exchange, the Company issued 5,505,200 shares of common stock (on a post-Share Exchange basis) to four officers, valued at $2,342,813, for the conversion of accrued salaries. The difference of $469,997 between the balance of accrued salaries and the fair value of the shares issued was recorded as a capital contribution recorded within additional paid-in capital. The transaction was viewed as being on behalf of the Company in connection with the pending share exchange transaction. In July 2018, the Company issued 2,030,000 shares of common stock, to an entity commonly controlled by the $500,000 convertible note holder, in exchange for $203,000. As of June 30, 2019 and December 31, 2018, there were 69,854,141 shares of common stock issued and outstanding, respectively. See Note 8 and 9 for discussion of the conversion of notes payable and accrued interest into commons stock. The Company determined fair value of its shares of common and preferred stock based on the price at which the Company was selling its shares of common and preferred stock to third party investors. Stock Options On September 1, 2017, the Company entered into an agreement for consulting services. As compensation the Company issued a stock option to purchase 100,000 shares of common stock at a price of $2.00 per share and is exercisable for five years. The stock option vests in equal monthly installments of 24 months. These options were valued at $20,154 using a Black-Scholes Options Pricing Model. For the three months ended June 30, 2019 and 2018, the Company recorded $2,519 as stock based compensation, which is included in the general and administrative expenses, in the statement of operations. For the six months ended June 30, 2019 and 2018, the Company recorded $5,038 as stock based compensation, which is included in the general and administrative expenses, in the statement of operations.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 14 – Subsequent Events From July 1, 2019 through the issuance of these condensed consolidated financial statements, there were no transactions of MJNA stock. The Company recognized an unrealized loss of $145,500 based on the closing price on August 5, 2019.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP.
Principles of Consolidation	Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Kannalife. The non-controlling interest in Kannalife represents the 0.30% equity interest held by the original shareholders of Kannalife before the share exchange. All significant consolidated transactions and balances have been eliminated in consolidation. The operations of Kannalife, Inc. are included in the consolidated financial statement from the date of the Share Exchange.
Significant risks and uncertainties	Significant risks and uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Company’s stock, stock based compensation, and valuation allowance relating to the Company’s deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made.
Concentration Risks	Concentration Risks During the six months ended June 30, 2019, the Company’s revenue had a concentration of 100% from one grant. The concentration of the Company’s revenue creates a potential risk to future working capital in the event that the Company is not able to continue receiving the grant revenue.
Joint Venture	Joint Venture On June 18, 2019, the Company, along with MJNA which is a significant shareholder and AXIM biotechnologies whose president is affiliated with a shareholder, entered into a joint venture agreement with an industrial hemp production farm for the supply of certain industrial hemp CBD crops. The purpose of the joint venture is to share in the harvested yield of the hemp production which the Company hopes to result in a steady industrial hemp CBD supply for research and development purposes. The Company accounts for its participation in the joint venture under the equity method of accounting.
Revenue Recognition	Revenue Recognition The FASB issued Accounting Standards Update (“ASU”) No. 2014-09, codified as ASC 606: Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The Company adopted ASC 606 effective January 1, 2018 using modified retrospective basis and the cumulative effect was immaterial to the consolidated financial statements. Revenue consists of research funding from the Company’s National Institute of Health (“NIH”) Grant. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met.
Stock Based Compensation	Stock Based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provision of FASB ASC 718, Compensation – Stock Compensation The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505, Equity–based Payments to Non-Employees .
Net Income (Loss) per Share	Net Income (Loss) per Share Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 5,150,000 for the three and six months ended June 30, 2019. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was zero (0) for the three and six months ended June 30, 2018.
Research and Development	Research and Development In accordance with FASB ASC 730, Research and Development
Recently Issued Authoritative Guidance	Recently Issued Authoritative Guidance In February 2016, the FASB issued ASU, Leases, which requires lessees to recognize most leases on their balance sheets as a right-of-use asset with a corresponding lease liability. Lessor accounting under the standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required. The Company adopted the standard effective January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the following accounting policies related to this standard update: • The option to not reassess prior conclusions related to the identification, classification and accounting for initial direct costs for leases that commenced prior to January 1, 2019. • Short-term lease accounting policy election allowing lessees to not recognize right-of-use assets and liabilities for leases with a term of 12 months or less; and • The option to not separate lease and non-lease components for certain equipment lease asset categories such as freight car, vehicles and work equipment. • The package of practical expedients applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. The Company has inventoried all leases where the Company is a lessee as of the initial date of application and has examined other contracts with suppliers, vendors, customers and other outside parties to identify whether such contracts contain an embedded lease as defined under the new guidance. The Company’s lease population comprises of an office and lab, which is immaterial to the consolidated financial statements. As a result of the above, the adoption of ASC 842 did not have a material effect on the financial statements. The Company will review for the existence of embedded leases in future agreements. In June 2018, the FASB issued ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. This standard is effective for public companies for annual periods beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted as long as ASU 2014-09 has been adopted. The Company adopted the guidance on January 1, 2019. The adoption did not have a material impact on our consolidated financial statements.

Organization and Nature of Op_2

Organization and Nature of Operations (Tables)	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule Of Pre-Acquisition Assets And Liabilities	Cash and cash equivalents $ 289,654 Note receivable 142,500 Total assets $ 432,154 Accounts payable and accrued expenses $ 20,504 Loan payable - related party - long term 41,995 Convertible notes payable - related party 500,000 Total liabilities 562,499 Total liabilities assumed $ (130,345 )
Schedule Of Consolidated Pro Forma Information Showing Results Of Operations	Pro Forma (Unaudited) Six Months Ended June 30, 2018 Total revenues $ 66,864 Net income $ 2,836,768 Net income per common share, basic $ 0.05 Net income per common share, diluted $ 0.05

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Schedule Of Assets That Are Measured And Recognized At Fair Value	June 30, 2019 Level 1 Level 2 Level 3 Total Carrying Value Marketable securities – Medical Marijuana, Inc. $ 805,500 — — $ 805,500

Accrued Payroll and Payroll T_2

Accrued Payroll and Payroll Taxes (Tables)	6 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Schedule Of Accrued Payroll And Payroll Taxes	2019 2018 Payroll $ — $ — Payroll taxes 249,537 246,067 Totals $ 249,537 $ 246,067

Marketable Security (Tables)

Marketable Security (Tables)	6 Months Ended
	Jun. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Schedule of gains and lossed on marketable securities	Net gains and (losses) recognized during the period on equity securities $ (213,664 ) Less: Net gains and (losses) recognized during the period on equity securities sold during the period 104,165 Unrealized gains and (losses) recognized during the period on equity securities still held at the reporting date $ (109,499 ) The following table summarizes the gains and losses recognized during the six month period ending June 30, 2019: Net gains and (losses) recognized during the period on equity securities $ (543,010 ) Less: Net gains and (losses) recognized during the period on equity securities sold during the period 91,011 Unrealized gains and (losses) recognized during the period on equity securities still held at the reporting date $ (451,999 )

Organization and Nature of Op_3

Organization and Nature of Operations - Schedule Of Pre-Acquisition Assets And Liabilities (Details)	Jun. 30, 2019USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 289,654
Note receivable	142,500
Total assets	432,154
Accounts payable and accrued expenses	20,504
Loan payable - related party - long term	41,995
Convertible notes payable - related party	500,000
Total liabilities	562,499
Total liabilities assumed	$ (130,345)

Organization and Nature of Op_4

Organization and Nature of Operations - Schedule Of Consolidated Pro Forma Information Showing Results Of Operations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Total revenues	$ 52,768	$ 36,858	$ 102,059	$ 66,864
Net income	$ (784,416)	$ 3,063,319	$ (1,632,915)	$ 2,911,984
Net income per common share, basic	$ (0.01)	$ 0.05	$ (0.02)	$ 0.05
Net income per common share, diluted	$ (.01)	$ .05	$ (.02)	$ .05
Pro Forma
Total revenues			$ 66,864
Net income			$ 2,836,768
Net income per common share, basic			$ 0.05
Net income per common share, diluted			$ 0.05

Organization and Nature of Op_5

Organization and Nature of Operations (Details Narrative)	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of Incorporation	Mar. 25, 2013
Former Legal or Registered Name	TYG Solutions Corp

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Accounting Policies [Abstract]
Weighted average number of common stock, anti-dilutive	5,150,000	0	5,150,000	0
Research and Development	$ 148,959	$ 34,871	$ 250,237	$ 58,637

Going Concern and Management'_2

Going Concern and Management's Liquidity Plans (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss from operations	$ (554,772)	$ (93,324)	$ (1,057,945)	$ (179,208)
Net cash used in operating activities			(1,303,127)	(300,630)
Accumulated deficit	(6,680,091)		(6,680,091)		$ (5,052,051)
Cash and cash equivalents	537,087	$ 48,696	537,087	$ 48,696	307,131	$ 4,326
Marketable security (available for sale)	$ 805,500		$ 805,500		$ 2,579,640

Fair Value Measurements - Sched

Fair Value Measurements - Schedule Of Assets That Are Measured And Recognized At Fair Value (Details)	Jun. 30, 2019USD ($)
Level 1
Marketable securities - Medical Marijuana, Inc.	$ 805,500
Level 2
Marketable securities - Medical Marijuana, Inc.
Level 3
Marketable securities - Medical Marijuana, Inc.
Total Carrying Value
Marketable securities - Medical Marijuana, Inc.	$ 805,500

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Jul. 31, 2018	Jan. 03, 2018	Apr. 30, 2014
Fair Value Disclosures [Abstract]
Restricted common stock exchanged					6,408,980
Fair value of common stock	$ 6,985	$ 6,985	$ 203,000	$ 2,342,813	$ 256,359
Per share value of common stock	$ .0001	$ .0001			$ 0.04

Accrued Payroll and Payroll T_3

Accrued Payroll and Payroll Taxes - Schedule Of Accrued Payroll And Payroll Taxes (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accrued Payroll And Payroll Taxes - Schedule Of Accrued Payroll And Payroll Taxes
Payroll
Payroll taxes	249,537	246,067
Totals	$ 249,537	$ 246,067

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Jun. 29, 2018
Debt Disclosure [Abstract]
Promissory note value					$ 352,500	$ 367,500
Interest rate					3.00%	3.00%	8.00%
Maturity date					Jul. 1, 2020	Jul. 1, 2020
Accrued interest			$ 48,921		$ 24,460
Loan payable - long term	$ 620,000		620,000		$ 620,000
Interest expense	$ 12,230	$ 4,514	$ 24,460	$ 8,150

Notes Payable - Related Party (

Notes Payable - Related Party (Details Narrative) - USD ($)	7 Months Ended	12 Months Ended
	Jul. 25, 2018	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2019	Jun. 29, 2018
Maturity date		Jul. 1, 2020	Jul. 1, 2020
Interest rate		3.00%	3.00%		8.00%
Related Party Promissory Note
Note payable, related party	$ 25,822
Maturity date	Mar. 31, 2020
Interest rate	0.05%
Accrued interest, related party note		$ 226		$ 226

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Jul. 31, 2018	Jun. 29, 2018	Jan. 03, 2018	Dec. 31, 2017	Nov. 25, 2015	Aug. 13, 2015	Jul. 24, 2015	May 15, 2015	Dec. 27, 2014
Interest rate		3.00%		8.00%		3.00%
Common stock issued	69,854,141	69,854,141	2,030,000		5,505,200
Convertible Debt
Convertible debt							$ 100,000	$ 50,000	$ 500,000	$ 35,000	$ 150,000
Maturity date							Nov. 24, 2016	Aug. 12, 2016	Feb. 16, 2030	Apr. 3, 2016	Dec. 31, 2018
Interest rate							10.00%	10.00%	3.00%	10.00%	10.00%
Convertible price per share							$ 1	$ 1	$ .10	$ 1	$ 1
Warrants issued							50,000	25,000		17,500
Value of warrants							$ 21,500	$ 10,751		$ 7,525
Warrants per share value							$ 1.50	$ 1.50		$ 1.50
Common stock issued					563,063
Value of notes converted					$ 236,104

Convertible Notes Payable - R_2

Convertible Notes Payable - Related Party (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Jun. 30, 2019	Dec. 31, 2018	Jul. 31, 2018	Jun. 29, 2018	Jan. 03, 2018	Dec. 31, 2016	Dec. 31, 2015	Nov. 25, 2015	Nov. 20, 2015	Aug. 13, 2015	Jul. 24, 2015	May 15, 2015	Dec. 27, 2014
Interest rate	3.00%		3.00%		8.00%
Repayment of convertible notes	$ 23,828
Repayment of accrued interest	16,522
Common stock issued		69,854,141	69,854,141	2,030,000		5,505,200
Convertible Debt
Convertible debt									$ 100,000		$ 50,000	$ 500,000	$ 35,000	$ 150,000
Maturity date									Nov. 24, 2016		Aug. 12, 2016	Feb. 16, 2030	Apr. 3, 2016	Dec. 31, 2018
Interest rate									10.00%		10.00%	3.00%	10.00%	10.00%
Convertible price per share									$ 1		$ 1	$ .10	$ 1	$ 1
Common stock issued						563,063
Value of notes converted						$ 236,104
Convertible Debt | Chief Executive Officer
Convertible debt	$ 20,000						$ 15,000	$ 120,000		$ 5,000
Interest rate	10.00%						10.00%	10.00%		10.00%
Convertible price per share	$ 0.40						$ .40	$ 1		$ .40
Convertible Debt (2) | Chief Executive Officer
Convertible debt							$ 10,000
Interest rate							10.00%
Convertible price per share							$ .40
Convertible Debt - Related Party
Common stock issued						973,946
Value of notes converted						$ 356,176
Loss on conversion of debt						$ 58,300

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Jul. 31, 2018	Jul. 01, 2018	Sep. 15, 2015	Apr. 01, 2014
Security Deposit	$ 17,121	$ 17,121
Office Space
Monthly Rent				$ 2,600	$ 249	$ 5,400
Security Deposit				$ 2,121	$ 183	$ 15,000
Laboratory Space
Monthly Rent			$ 500

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Related Party Transactions [Abstract]
Due from related party	$ 2,456	$ 16,334

Marketable Security - Marketabl

Marketable Security - Marketable Security - Schedule of gains and lossed on marketable securities (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Net gains and (losses) recognized during the period on equity securities	$ (213,664)	$ (543,010)
Less: Net gains and (losses) recognized during the period on equity securities sold during the period	104,165	91,011
Unrealized gains and (losses) recognized during the period on equity securities still held at the reporting date	$ (109,499)	$ (451,999)

Marketable Security (Details Na

Marketable Security (Details Narrative) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Marketable securities in MJNA	15,000,000
Marketable securities, per share	$ .0537
Marketable security (available for sale)	$ 805,500	$ 2,579,640

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2018	Jan. 03, 2018	Apr. 30, 2014
Preferred Stock, Par or Stated Value Per Share	$ .0001				$ .0001			$ .0001
Preferred Stock, Shares Authorized	5,000,000				5,000,000			5,000,000
Common Stock Description					<font style="font-size: 10pt">All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders.</font></p>" id="sjs-F5">&lt;p style="margin: 0; text-align: justify">&lt;font style="font-size: 10pt">All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders.&lt;/font>&lt;/p>
Common Stock, Par or Stated Value Per Share	$ .0001				$ .0001			$ .0001			$ 0.04
Common Stock, Shares Authorized	200,000,000				200,000,000			200,000,000
Common Stock, Shares, Issued	69,854,141				69,854,141			69,854,141	2,030,000	5,505,200
Common Stock, Shares, Outstanding	69,854,141				69,854,141			69,854,141
Common stock value	$ 6,985				$ 6,985			$ 6,985	$ 203,000	$ 2,342,813	$ 256,359
Capital contribution	6,386,793				6,386,793			$ 6,381,755		$ 469,997
Options granted							100,000
Options granted, exercise price							$ 2
Vesting period							5 years
Issuance of options for services					5,038	$ 5,038
Issuance of stock options for services	$ 2,519	$ 2,519	$ 2,520	$ 2,519	$ 2,519
Series A Preferred Stock [Member]
Preferred stock description					<font style="font-size: 10pt">The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Company’s board of directors and any annual or special meeting and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share.</font></p>" id="sjs-F18">&lt;p style="margin: 0pt; text-align: justify">&lt;font style="font-size: 10pt">The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Company&#8217;s board of directors and any annual or special meeting and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share.&lt;/font>&lt;/p>
Preferred Stock, Shares Authorized	75		75		75	75
Preferred Stock, Shares Issued	75		75		75	75			75
Preferred Stock Issued, Value									$ 75,000
Preferred Stock, Shares Outstanding	75		75		75	75
Series B Preferred Stock [Member]
Preferred stock description					<font style="font-size: 10pt">Each share of the Series B Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series B Preferred Stock are entitled to elect up to three (3) directors to the Company’s board of directors and any annual or special meeting and have preferential rights in regard to the election of Series B directors. In all other voting matters, the holders of Series B Preferred Stock are entitled to cast 1,000 votes per share.</font></p>" id="sjs-F24">&lt;p style="margin: 0pt; text-align: justify">&lt;font style="font-size: 10pt">Each share of the Series B Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company&#8217;s common stock. The holders of a majority of the Series B Preferred Stock are entitled to elect up to three (3) directors to the Company&#8217;s board of directors and any annual or special meeting and have preferential rights in regard to the election of Series B directors. In all other voting matters, the holders of Series B Preferred Stock are entitled to cast 1,000 votes per share.&lt;/font>&lt;/p>
Preferred Stock, Shares Authorized	75		75		75	75
Preferred Stock, Shares Issued	75		75		75	75			75
Preferred Stock Issued, Value									$ 75,000
Preferred Stock, Shares Outstanding	75		75		75	75

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	1 Months Ended
	Aug. 14, 2019USD ($)
Subsequent Events [Abstract]
Unrealized loss	$ 145,500